| |
Newsroom /
Health and Fitness
/
Healthcare
/
Addiction Control – Drug Pipeline Analysis and Market Forecasts to 2015
Addiction Control – Drug Pipeline Analysis and Market Forecasts to 2015
Addiction Control Therapeutics Market is Forecasts to Show Significant Growth until 2015
Hyderabad,
AP,
India
(prbd.net)
06/01/2010
"The global addiction control therapeutics market is expected to grow to $5.3 billion with a CAGR of 10% by year 2015. "
The global addiction control therapeutics market was valued at $2.7 billion in 2008 and will be driven by the increasing addictive population. This market is expected to grow to $5.3 billion with a CAGR of 10% by year 2015.
As the market has fewer treatment options, patients and physicians are not left with much choice, which translates into high prescription rates of existing branded products and other generic products, which keeps market growing. In addition, the successful launch of some of the vaccines such as NicVAX, TA-NIC and TA-CD, currently in Phase II will significantly stimulate the market growth. However, the lack of any novel therapeutic with curative properties and the patent expiry of the current market therapies such as Suboxone/Subutex and Campral will pose a barrier for market growth.
GlobalData has found that products for addiction control in the developmental pipeline are strong with over 240 molecules in various phases of clinical development. There are over 20 first-in-class molecules in different stages of clinical development. These molecules have distinct advantages over the current marketed players in term of better efficacy and safety profiles. These molecules are primarily first-in-class molecules, which demonstrates the robustness of the addiction control pipeline as the market is demanding new entrants with novel treatments and re-formulation designs to offer long-term abstinence and high safety profiles.
There are 41 molecules in Phase III making up to 17% of overall pipeline. The Phase II clinical stage has highest contribution with over 146 molecules making up to 59% of the addiction control pipeline. NicVAX, TA-NIC, TA-CD, Revex, CYT002-NicQb and other promising molecules with features such as better efficacy, better tolerability and safety profiles are the most keenly watched products in addiction control pipeline portfolio.
The current competition is weak and the marketed products are unsuccessful in meeting the patients’ demands leaving behind a larger segment of unmet need. Because the products currently in market do not serve the unmet need of curing the disease, the market continues to present opportunities for stronger pipeline candidates. The current drugs are mainly offering brief withdrawal from addictive substances. Additionally, the current market is mainly driven by a smaller number of branded drugs and generics. This underexploited market holds significant market potential for any new entrants with disease modifying capability. Designing disease modifying drugs rather than drugs for brief withdrawal is one of key challenges for this market and could provide a significant opportunity for any company.
GlobalData, the industry analysis specialist, has released a new report, “Addiction Control – Drug Pipeline Analysis and Market Forecasts to 2015.” The report is an essential source of information and analysis on the global addiction control market. The report identifies the key trends shaping and driving the global addiction control market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global addiction control sector.
Or Visit our report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|